Login to Your Account

Regenerative Medicine Specialist Mesoblast Lands $174.6M

By Nuala Moran
Staff Writer

Friday, March 8, 2013
LONDON – Mesoblast Ltd. has raised A$170 million (US$174.6 million) in a private placing, bringing total cash reserves for the stem cell specialist to A$332 million and providing funding for a Phase III trial in treating degenerating spinal discs.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription